

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

William J. Curatolo et al.

Application No. 09/770,562

Filed: January 26, 2001

Confirmation No. 8513

For: SOLID PHARMACEUTICAL DISPERSIONS
WITH ENHANCED BIOAVAILABILITY

Examiner: Blessing M. Fubara

Art Unit: 1613

Attorney Reference No. 8191-87018-01

FILED VIA EFS
ON 2/28/2012

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language and/or non-English-language documents. The non-English-language documents contain English-language abstracts. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted electronically herewith is the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with § 1.97(c).


Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Lisa M. Caldwell
Registration No. 41,653

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301